+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Fibrinogen Concentrate Market By Indication, By End User: Global Opportunity Analysis and Industry Forecast, 2024-2035

  • PDF Icon

    Report

  • 280 Pages
  • May 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994146
Description Jump to:
The global Human Fibrinogen Concentrate Market size was valued at $0.8 billion in 2023 and is projected to reach $2.9 billion by 2035, registering a CAGR of 11% from 2023 to 2035.

Human fibrinogen is a soluble plasma glycoprotein that plays a vital role in blood clot formation as a key clotting factor. Fibrinogen concentrate receives detailed attention for managing acute bleeding incidents in patients with bleeding disorders. This glycoprotein is used as a medicinal treatment for blood disorders in vertebrates, aids in clot formation. Human fibrinogens concentrate significantly improve the firmness of whole blood clots and reduces the need for postoperative transfusions in severely bleeding patients. Factors such as increase in use of fibrinogen concentrate for bleeding patients and congenital deficiency treatment are propelling the growth of the global market.

Human fibrinogens are currently used in several surgical specialties, including cardiovascular surgery, urological surgery, pulmonary surgery, wound management, orthopedic surgery, ophthalmic surgery, neurosurgery, plastic and reconstructive surgery, and dental surgery to reduce blood loss. Human fibrinogen is used for sealing tissue during surgery. Human fibrinogen helps in reducing blood loss and to stop blood flow during surgeries and in wound management. Human fibrinogens mimic the final steps of the physiological coagulation cascade to form a fibrin clot. Use of human fibrinogen can also reduce perioperative and postoperative complications by reducing fluid leakage, air leakage, and by preventing fistulae formation. Human fibrinogen has a unique physiologic action, and the resulting fibrin clot is fully degraded by the body's natural wound healing process.

The Human Fibrinogen Concentrate Market share has witnessed growth, owing to increase in geriatric population that are prone to chronic diseases, and rise in prevalence of diseases such as gastric diseases, heart attack, atherosclerosis disease, ischemic stroke, aneurysm, tumors, blood clot in brain, cancer, myocardial infarction, arrythmia, increases in blockages of blood vessel in heart, brain, kidney and liver is led to increase in number surgeries. Rise in sports injuries and road accidents is also increasing the demand for human fibrinogen products. Hence, all such factors boost the growth of the Human Fibrinogen Concentrate Market size.

For instance, according to health hearty 2020 report, the incident rate of heart attacks per 10,000 people is around 190 in people who are over 85 years of age, around 117 for those between 75-84 years of age. According to the National Center for Health Statistics, every year, more than 795,000 people in the U.S. have a stroke.

However, unfavorable reimbursements and complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers globally in the future.

Major companies operating in the market include CSL Behring GmbH, Octapharma USA, Grifols, S.A., LFB Biomedicaments, Shanghai RAAS Blood Products Co., Ltd., Takeda Pharmaceutical Company Limited, Baxter International Inc., Biotest AG, BioRad, and Harbin Pacific Biopharmaceutical Co., Ltd. Key players have adopted partnership and collaboration as their key strategy to improve the product portfolio of the Human Fibrinogen Concentrate Market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the human fibrinogen market analysis from 2023 to 2035 to identify the prevailing human fibrinogen market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the human fibrinogen market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global human fibrinogen market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Average Selling Price Analysis / Price Point Analysis
  • Brands Share Analysis
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Import Export Analysis/Data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • List of customers/consumers/raw material suppliers- value chain analysis
  • Market share analysis of players at global/region/country level
  • Per Capita Consumption Trends
  • Product Consumption Analysis
  • Reimbursement Scenario
  • SWOT Analysis
  • Volume Market Size and Forecast

Key Market Segments

By Form

  • Lyophilized
  • Powder
  • Liquid

By End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Indication

  • Surgical Procedure
  • Congenital Fibrinogen Deficiency

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • CSL Limited
  • Grifols, S.A.
  • Intas Pharmaceuticals Limited
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • The LFB group

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Congenital Fibrinogen Deficiency
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Surgical Procedure
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM
5.1. Overview
5.1.1. Market size and forecast
5.2. Lyophilized
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Powder
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Liquid
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Ambulatory Surgical Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Indication
7.2.3. Market size and forecast, by Form
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Indication
7.2.5.1.2. Market size and forecast, by Form
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Indication
7.2.5.2.2. Market size and forecast, by Form
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Indication
7.2.5.3.2. Market size and forecast, by Form
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Indication
7.3.3. Market size and forecast, by Form
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Indication
7.3.5.1.2. Market size and forecast, by Form
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Indication
7.3.5.2.2. Market size and forecast, by Form
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Indication
7.3.5.3.2. Market size and forecast, by Form
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Indication
7.3.5.4.2. Market size and forecast, by Form
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Indication
7.3.5.5.2. Market size and forecast, by Form
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Indication
7.3.5.6.2. Market size and forecast, by Form
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Indication
7.4.3. Market size and forecast, by Form
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Indication
7.4.5.1.2. Market size and forecast, by Form
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Indication
7.4.5.2.2. Market size and forecast, by Form
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. Australia
7.4.5.3.1. Market size and forecast, by Indication
7.4.5.3.2. Market size and forecast, by Form
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. India
7.4.5.4.1. Market size and forecast, by Indication
7.4.5.4.2. Market size and forecast, by Form
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Indication
7.4.5.5.2. Market size and forecast, by Form
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Indication
7.4.5.6.2. Market size and forecast, by Form
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Indication
7.5.3. Market size and forecast, by Form
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Indication
7.5.5.1.2. Market size and forecast, by Form
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Indication
7.5.5.2.2. Market size and forecast, by Form
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Indication
7.5.5.3.2. Market size and forecast, by Form
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Indication
7.5.5.4.2. Market size and forecast, by Form
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. CSL Limited
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Octapharma AG
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Shanghai RAAS Blood Products Co., Ltd.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. The LFB group
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Grifols, S.A.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Intas Pharmaceuticals Limited
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 02. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR CONGENITAL FIBRINOGEN DEFICIENCY, BY REGION, 2023-2035 ($MILLION)
TABLE 03. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR SURGICAL PROCEDURE, BY REGION, 2023-2035 ($MILLION)
TABLE 04. GLOBAL HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 05. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR LYOPHILIZED, BY REGION, 2023-2035 ($MILLION)
TABLE 06. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR POWDER, BY REGION, 2023-2035 ($MILLION)
TABLE 07. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR LIQUID, BY REGION, 2023-2035 ($MILLION)
TABLE 08. GLOBAL HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 09. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR HOSPITALS, BY REGION, 2023-2035 ($MILLION)
TABLE 10. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2023-2035 ($MILLION)
TABLE 11. HUMAN FIBRINOGEN CONCENTRATE MARKET FOR OTHERS, BY REGION, 2023-2035 ($MILLION)
TABLE 12. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY REGION, 2023-2035 ($MILLION)
TABLE 13. NORTH AMERICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 14. NORTH AMERICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 15. NORTH AMERICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 16. NORTH AMERICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 17. U.S. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 18. U.S. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 19. U.S. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 20. CANADA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 21. CANADA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 22. CANADA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 23. MEXICO HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 24. MEXICO HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 25. MEXICO HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 26. EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 27. EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 28. EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 29. EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 30. GERMANY HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 31. GERMANY HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 32. GERMANY HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 33. FRANCE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 34. FRANCE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 35. FRANCE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 36. UK HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 37. UK HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 38. UK HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 39. ITALY HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 40. ITALY HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 41. ITALY HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 42. SPAIN HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 43. SPAIN HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 44. SPAIN HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 45. REST OF EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 46. REST OF EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 47. REST OF EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 48. ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 49. ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 50. ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 51. ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 52. JAPAN HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 53. JAPAN HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 54. JAPAN HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 55. CHINA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 56. CHINA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 57. CHINA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 58. AUSTRALIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 59. AUSTRALIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 60. AUSTRALIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 61. INDIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 62. INDIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 63. INDIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 64. SOUTH KOREA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 65. SOUTH KOREA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 66. SOUTH KOREA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 70. LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 71. LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 72. LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 73. LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
TABLE 74. BRAZIL HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 75. BRAZIL HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 76. BRAZIL HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 77. SAUDI ARABIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 78. SAUDI ARABIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 79. SAUDI ARABIA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 80. SOUTH AFRICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 81. SOUTH AFRICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 82. SOUTH AFRICA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 83. REST OF LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023-2035 ($MILLION)
TABLE 84. REST OF LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023-2035 ($MILLION)
TABLE 85. REST OF LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023-2035 ($MILLION)
TABLE 86. CSL LIMITED: KEY EXECUTIVES
TABLE 87. CSL LIMITED: COMPANY SNAPSHOT
TABLE 88. CSL LIMITED: PRODUCT SEGMENTS
TABLE 89. CSL LIMITED: SERVICE SEGMENTS
TABLE 90. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 91. CSL LIMITED: KEY STRATEGIES
TABLE 92. OCTAPHARMA AG: KEY EXECUTIVES
TABLE 93. OCTAPHARMA AG: COMPANY SNAPSHOT
TABLE 94. OCTAPHARMA AG: PRODUCT SEGMENTS
TABLE 95. OCTAPHARMA AG: SERVICE SEGMENTS
TABLE 96. OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 97. OCTAPHARMA AG: KEY STRATEGIES
TABLE 98. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: KEY EXECUTIVES
TABLE 99. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: COMPANY SNAPSHOT
TABLE 100. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: PRODUCT SEGMENTS
TABLE 101. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: SERVICE SEGMENTS
TABLE 102. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: PRODUCT PORTFOLIO
TABLE 103. SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.: KEY STRATEGIES
TABLE 104. THE LFB GROUP: KEY EXECUTIVES
TABLE 105. THE LFB GROUP: COMPANY SNAPSHOT
TABLE 106. THE LFB GROUP: PRODUCT SEGMENTS
TABLE 107. THE LFB GROUP: SERVICE SEGMENTS
TABLE 108. THE LFB GROUP: PRODUCT PORTFOLIO
TABLE 109. THE LFB GROUP: KEY STRATEGIES
TABLE 110. GRIFOLS, S.A.: KEY EXECUTIVES
TABLE 111. GRIFOLS, S.A.: COMPANY SNAPSHOT
TABLE 112. GRIFOLS, S.A.: PRODUCT SEGMENTS
TABLE 113. GRIFOLS, S.A.: SERVICE SEGMENTS
TABLE 114. GRIFOLS, S.A.: PRODUCT PORTFOLIO
TABLE 115. GRIFOLS, S.A.: KEY STRATEGIES
TABLE 116. INTAS PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 117. INTAS PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 118. INTAS PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 119. INTAS PHARMACEUTICALS LIMITED: SERVICE SEGMENTS
TABLE 120. INTAS PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 121. INTAS PHARMACEUTICALS LIMITED: KEY STRATEGIES
LIST OF FIGURES
FIGURE 01. HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035
FIGURE 02. SEGMENTATION OF HUMAN FIBRINOGEN CONCENTRATE MARKET,2023-2035
FIGURE 03. TOP IMPACTING FACTORS IN HUMAN FIBRINOGEN CONCENTRATE MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN HUMAN FIBRINOGEN CONCENTRATE MARKET (2024-2035)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL HUMAN FIBRINOGEN CONCENTRATE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION, 2023 AND 2035(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR CONGENITAL FIBRINOGEN DEFICIENCY, BY COUNTRY 2023 AND 2035(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR SURGICAL PROCEDURE, BY COUNTRY 2023 AND 2035(%)
FIGURE 14. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM, 2023 AND 2035(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR LYOPHILIZED, BY COUNTRY 2023 AND 2035(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR POWDER, BY COUNTRY 2023 AND 2035(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR LIQUID, BY COUNTRY 2023 AND 2035(%)
FIGURE 18. HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER, 2023 AND 2035(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2035(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY 2023 AND 2035(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF HUMAN FIBRINOGEN CONCENTRATE MARKET FOR OTHERS, BY COUNTRY 2023 AND 2035(%)
FIGURE 22. HUMAN FIBRINOGEN CONCENTRATE MARKET BY REGION, 2023 AND 2035(%)
FIGURE 23. U.S. HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 24. CANADA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 25. MEXICO HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 26. GERMANY HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 27. FRANCE HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 28. UK HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 29. ITALY HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 30. SPAIN HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 31. REST OF EUROPE HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 32. JAPAN HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 33. CHINA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 34. AUSTRALIA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 35. INDIA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 36. SOUTH KOREA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 38. BRAZIL HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 39. SAUDI ARABIA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 40. SOUTH AFRICA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 41. REST OF LAMEA HUMAN FIBRINOGEN CONCENTRATE MARKET, 2023-2035 ($MILLION)
FIGURE 42. TOP WINNING STRATEGIES, BY YEAR (2021-2022)
FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2022)
FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY (2021-2022)
FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 46. COMPETITIVE DASHBOARD
FIGURE 47. COMPETITIVE HEATMAP: HUMAN FIBRINOGEN CONCENTRATE MARKET
FIGURE 48. TOP PLAYER POSITIONING, 2023

Companies Mentioned

  • CSL Limited
  • Grifols, S.A.
  • Intas Pharmaceuticals Limited
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • The LFB group

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages280
PublishedMay 2024
Forecast Period2023 - 2035
Estimated Market Value ( USD ) in 2023 $ 0.8 billion
Forecasted Market Value ( USD ) by 2035 $ 2.9 billion
Compound Annual Growth Rate11.0%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Human Fibrinogen Concentrate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Human Fibrinogen Concentrate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 83 Pages
  • Global
From
Human Fibrinogen Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type - Product Image

Human Fibrinogen Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 83 Pages
  • Global
From
Hypofibrinogenemia - Pipeline Insight, 2024 - Product Image

Hypofibrinogenemia - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Global Coagulation Factor Concentrates Market by Type of Coagulation Factor, Product Formulation, Application, End-User - Forecast 2024-2030 - Product Image

Global Coagulation Factor Concentrates Market by Type of Coagulation Factor, Product Formulation, Application, End-User - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From
Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.